💉 $25.25, -1.33% as of Aug-11-2025 🩸💰

🚨 Insider Lifeline: CEO & Director Open Wallets

In the middle of a tough quarter, Centene’s top brass just swiped their corporate AmEx for a little self-care investing:

💡 Translation: They’re buying at levels not seen since the pre-AirPods era. Either they see deep value… or they’re stocking up on Tums.

Can Centene Get Any Cheaper Than This?

Insiders had already bought at more than double the current price just about six months ago… and we’ve got receipts. 👇

📦 The Insider Box Score

Back in Dec 2024, directors and executives went on a shopping spree around $59–60 per share:

• 🧠 Thomas Greco (Dir): $1.02M @ $59.75

• 📊 Andrew Asher (CFO): $1.0M @ $58.14

• 👩💼 Sarah London (CEO): $250K @ $60.80

• (And others — all above $58/share)

Today? Shares are less than half that. Bargain-bin Centene, anyone?

Bar chart showing Centene insider buys exceeding $3M around $60/share in 2024.

🧠 Institutions Think Math Is Optional

Institutions own more than 100% of the float. That’s not a typo.
It’s Wall Street’s version of:

“We believe in this stock so much… we’ll borrow shares we don’t have.”

• 🧢 Vanguard: 57.5M shares

• 🎩 BlackRock: 45.2M shares

• 💼 FMR, Norges Bank, State Street… they’re all in.

🔍 For Centene (CNC)'s Institutional Ownership breakdown, see here. 

🩺 Q2 2025: The Check-Up (Spoiler: Needs a Second Opinion)

The Good ✅

• Premium & service revenues: $42.5B (+18% YoY) 📈

• PDP & Marketplace growth + Medicaid rate hikes = big top-line gains.

• Cash flow from ops: $1.8B 💵

The Bad ❌

• GAAP EPS: -$0.51 😬

• Adjusted EPS: -$0.16

• Health Benefits Ratio: 93% (vs. 87.6% last year) — meaning more cash going to patient care and less to profits.

The Ugly 🤢

• Medicaid & Marketplace costs surging (behavioral health, home care, expensive drugs 💊💸).

• Marketplace risk adjustment revenue drop = earnings migraine.

• Medicare Advantage premium deficiency reserve increase.

👉 Want the full picture? Dive into Centene (CNC)'s financials here.

📉 Valuation: From Blue Chip to Bargain Bin

Centene’s market cap has been cut by more than half in a year:

Thrift-store pricing — but beware: goodwill impairments and industry storms could make it cheaper before any bounce.

🐻 Bear Case: Why This Could Get Uglier

• Guidance cuts = investor indigestion.

• Medicaid redeterminations slicing enrollments.

• Healthcare cost inflation making risk models look like fortune cookies.

• Competitors (UNH, ELV) are also limping — sector-wide fever.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

🐂 Bull Case: Why This Could Be a Buy

• CEO & Director just bought in.

• Institutions own over 100% of the float (thanks, short lending).

• Technical support around $25 — same lows from 2015–2016.

• Valuation is more compelling.

🎯 Prognosis: High Risk, High Reward

Centene isn’t on hospice care, but it’s not running marathons either.

If you’re bold: Take a starter position, scale only if recovery signs show.
If you’re cautious: Wait for an uptrend — value traps can look like value feasts until they give you food poisoning.

💬 Verdict:
Centene is in the ER. The vitals are shaky, but the patient still has a pulse, a loyal institutional family, and a CEO willing to buy the dip. Recovery’s possible… but you’ll need patience and maybe a strong stomach.

🚨 Disclaimer:

This article is for entertainment and information only. We write crisply but we’re not licensed to prescribe stocks. Your portfolio, your call. Do your own research or consult a gene-edited financial advisor. 😄

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny